TriSalus Life Sciences, Inc. (TLSI) Investor Relations Documents

TriSalus Life Sciences, Inc. (TLSI) investor relations documents from the company's IR site: 1 presentation, 18 press releases; latest deck 2026-08-06. Read in-app with summaries. First-party data.

TriSalus Investor Presentation August 2026 — TriSalus Life Sciences is a commercial-stage medical technology company projecting 2026 revenues of $54–$57 million, driven by its Pressure Enabled Drug Delivery (PEDD) platform.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06PresentationTriSalus Investor Presentation August 2026
2026-08-06Press releaseTriSalus Life Sciences Reports Second Quarter 2026 Results
2026-07-29Press releaseTriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-07-16Press releaseTriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
2026-06-10Press releaseTriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug
2026-05-12Press releaseTriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitatin
2026-05-12Press releaseReal-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes an
2026-05-04Press releaseTriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tu
2026-04-28Press releaseTriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
2026-04-09Press releaseTriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
2026-04-07Press releaseTriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
2026-03-18Press releaseTriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Deli
2025-03-27Press releaseEarnings Release
2024-11-14Press releaseEarnings Release
2024-08-15Press releaseEarnings Release
2024-05-15Press releaseEarnings Release
2024-04-01Press releaseEarnings Release
2023-11-14Press releaseEarnings Release
Press releaseTriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pr

TLSI overview · TLSI earnings · TLSI financials · TLSI KPIs · TLSI ownership · TLSI peers · TLSI filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.